• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by ArriVent BioPharma Inc.

    11/14/25 4:46:07 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVBP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    ArriVent BioPharma, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    04272N102

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    04272N102


    1Names of Reporting Persons

    Octagon Capital Advisors LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,971,054.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,971,054.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,971,054.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    04272N102


    1Names of Reporting Persons

    Octagon Investments Master Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    776,667.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    776,667.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    776,667.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    PN, OO


    SCHEDULE 13G

    CUSIP No.
    04272N102


    1Names of Reporting Persons

    Octagon Private Opportunities Fund LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    799,911.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    799,911.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    799,911.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.0 %
    12Type of Reporting Person (See Instructions)

    PN, OO


    SCHEDULE 13G

    CUSIP No.
    04272N102


    1Names of Reporting Persons

    Octagon Special Opportunities Fund LP - Series 4
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    394,476.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    394,476.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    394,476.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.0 %
    12Type of Reporting Person (See Instructions)

    PN, OO


    SCHEDULE 13G

    CUSIP No.
    04272N102


    1Names of Reporting Persons

    Ting Jia
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CHINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,971,054.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,971,054.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,971,054.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ArriVent BioPharma, Inc.
    (b)Address of issuer's principal executive offices:

    18 Campus Boulevard, Suite 100, Newtown Square, PA, 19073
    Item 2. 
    (a)Name of person filing:

    This statement is being jointly filed by: Octagon Capital Advisors LP ("Octagon") Octagon Investments Master Fund LP ("Master Fund") Octagon Private Opportunities Fund LP ("Private Fund") Octagon Special Opportunities Fund LP - Series 4 ("Special Fund") Ting Jia, as the principal beneficial owner of Octagon ("Mr. Jia") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons." Octagon serves as the investment manager of the Master Fund, Private Fund and the Special Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer's Common Shares directly owned by the Master Fund, by the Private Fund and by the Special Fund.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065.
    (c)Citizenship:

    Octagon is a Delaware limited partnership. The Master Fund is an exempted limited partnership established in the Cayman Islands. The Private Fund is a Delaware limited partnership. The Special Fund is a Delaware limited partnership. Mr. Jia is a Chinese citizen.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    04272N102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,971,054
    (b)Percent of class:

    4.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,971,054

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,971,054 The percentage reported on this Schedule 13G is calculated based upon 40,568,944 Common Shares outstanding as of August 8, 2025, as reported in the Form 8-K filed by the Issuer on August 11, 2025.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Octagon is the investment advisor to the Master Fund, the Private Fund, the Special Fund and other accounts. Mr. Jia is the control person of Octagon. The Master Fund holds the Common Shares for the benefit of its investors. The Private Fund holds the Common Shares for the benefit of its investors. The Special Fund holds the Common Shares for the benefit of its investors. The Master Fund, the Private Fund, the Special Fund and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Octagon Capital Advisors LP
     
    Signature:/s/ Ting Jia
    Name/Title:Managing Member
    Date:11/14/2025
     
    Octagon Investments Master Fund LP
     
    Signature:/s/ Ting Jia
    Name/Title:Managing Member, Octagon Investments GP, LLC, its general partner
    Date:11/14/2025
     
    Octagon Private Opportunities Fund LP
     
    Signature:/s/ Ting Jia
    Name/Title:Managing Member, Octagon Investments GP, LLC, its general partner
    Date:11/14/2025
     
    Octagon Special Opportunities Fund LP - Series 4
     
    Signature:/s/ Ting Jia
    Name/Title:Managing Member, Octagon Investments GP, LLC, its general partner
    Date:11/14/2025
     
    Ting Jia
     
    Signature:/s/ Ting Jia
    Name/Title:Ting Jia
    Date:11/14/2025
    Get the next $AVBP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVBP

    DatePrice TargetRatingAnalyst
    12/10/2025$45.00Buy
    BTIG Research
    11/25/2025$43.00Buy
    Truist
    7/10/2025$33.00Buy
    Goldman
    3/20/2025$37.00Buy
    B. Riley Securities
    3/10/2025$45.00Buy
    Guggenheim
    7/22/2024$35.00Outperform
    Oppenheimer
    4/30/2024$25.00Buy
    H.C. Wainwright
    2/20/2024$35.00Buy
    Jefferies
    More analyst ratings

    $AVBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ArriVent BioPharma Reports Third Quarter 2025 Financial Results

    Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in ChinaEstablised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial OfficerCash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027 NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("Company" or "ArriVent") (Nasdaq: "AVBP"), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical

    11/10/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent Appoints Brent S. Rice as Chief Commercial Officer

    NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h

    9/22/25 4:05:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

    16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR) 14.6 months by BICR in first-line patientsConfirmed CNS (central nervous system) responses with firmonertinib including complete responses (CRs) by BICRFirmonertinib rapidly decreased or cleared PACC circulating tumor DNA (ctDNA) in frontline patients across PACC mutation types (frequent, less frequent and compound PACC) consistent with broad PACC activityEnrollment of the first patient in the global pivotal Phase 3 ALPACCA study in first-line EGFR PACC mutant non-small cell

    9/9/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Lachapelle Robin exercised 11,153 shares at a strike of $2.28, increasing direct ownership by 9% to 135,736 units (SEC Form 4)

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    7/15/25 7:00:15 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parsey Merdad

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    6/20/25 7:33:08 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Peterson Kristine

    4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

    6/20/25 7:32:41 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on ArriVent BioPharma with a new price target

    BTIG Research initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

    12/10/25 8:24:33 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on ArriVent BioPharma with a new price target

    Truist initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $43.00

    11/25/25 8:38:45 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on ArriVent BioPharma with a new price target

    Goldman resumed coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $33.00

    7/10/25 8:52:29 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ArriVent BioPharma Inc.

    SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/14/25 4:46:07 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ArriVent BioPharma Inc.

    10-Q - ArriVent BioPharma, Inc. (0001868279) (Filer)

    11/10/25 8:02:05 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

    11/10/25 8:00:09 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Leadership Updates

    Live Leadership Updates

    View All

    ArriVent BioPharma Reports Third Quarter 2025 Financial Results

    Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in ChinaEstablised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial OfficerCash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027 NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("Company" or "ArriVent") (Nasdaq: "AVBP"), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical

    11/10/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent Appoints Brent S. Rice as Chief Commercial Officer

    NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h

    9/22/25 4:05:00 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ArriVent BioPharma Reports First Quarter 2025 Financial Results

    Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

    5/12/25 8:00:00 AM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    12/4/24 4:32:39 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/14/24 4:33:47 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ArriVent BioPharma Inc.

    SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

    11/12/24 2:45:16 PM ET
    $AVBP
    Biotechnology: Pharmaceutical Preparations
    Health Care